C

oncerned about patent rights, two large pharmaceutical industry trade groups have asked U.S. trade officials to place the European Union on a so-called watch list of countries that, arguably, do not sufficiently protect intellectual property rights.

The move comes in response to a pair of European Commission reviews. One concerns incentives for patents and their impact on innovation and access to medicines. The other might rework “supplementary protection certificates,” which are essentially patent extensions, by offering waivers to third parties to make and export patent-protected drugs.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy